Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention
Hektoen Institute for Medical Research · with National Institutes of Health (NIH) · NCT05848570
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 13–34 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 6000
- US sites recruiting
- 1
- Study start
- March 23, 2023
- Record last updated
- May 8, 2023
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Despite advances in HIV diagnostics, care and prevention strategies, infection rates among adolescent and young adult sexual and gender minorities (SGM) continue to rise in the United States (US). There is an urgent need to describe the epidemiology and trajectories of HIV acquisition in this population and to offer age and culturally appropriate scalable prevention interventions to those at highest risk of infection in the US. This project will engage and retain young SGM in an innovative longitudinal cohort, enroll participants in a dynamic established digital health retention platform (HMP; HealthMPowerment), monitor HIV risk and prevention behaviors and explore the socioecological factors that influence the use of new HIV prevention technologies (UG3 phase), while also allowing targeted testing of novel digital health interventions (UH3 phase). In Aim 1, the investigators will enroll and retain a large (n=6000; 3000/year), diverse cohort of sexually active, SGM adolescents and young adults, ages 13-34, using innovative digital recruitment, engagement and retention strategies. Over the course of the study, the investigators will longitudinally characterize the sexual behavior, HIV transmission risk, and PrEP uptake trajectories of SGM youth utilizing epidemiological trajectory analyses to identify the most effective points of intervention (Aim 2). This study will capitalize upon productive existing partnerships and digital health expertise to articulate the drivers of the ongoing HIV epidemic among the most vulnerable populations in the US in order to identify the most effective, expeditious and scalable strategies to address this ongoing public health crisis.
Being studied: Keeping it LITE
Conditions: HIV Infections; Sexual Behavior
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- For young adults ages 18-34: self-identified SGM young adults ages 18-34 who meet at least one of the following criteria:
- 1) condomless anal or vaginal intercourse (CAI) with a cisgender man in the last 6 months OR
- 2) sex with cisgender men and bacterial STI in the last 6 months OR
- 3) anal or vaginal sex with a known HIV-infected partner in the last 6 months.
- For adolescents 13-17: self-identified SGM adolescents ages 13-17 who have engaged in any sexual activity (e.g., oral, anal or vaginal sex)
Exclusion Criteria
- under age 13
- over age 34
Recruiting US locations
John H. Stroger, Jr. Hospital of Cook County
Chicago, IL 60612
Site contact: Sybil Hosek, PhD · 312-864-8030 · shosek@cookcountyhhs.org
Study contacts (from the official record)
- Sybil Hosek, PhD · 3128648030 · shosek@cookcountyhhs.org
- Audrey French, MD · afrench@cookcountyhhs.org
Similar studies in Illinois
All healthy volunteers studies in Illinois →- RecruitingHealthy volunteers
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
University of Chicago
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Melrose Park, IL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
- Location
- Grayslake, IL + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
AbbVie
- Location
- Grayslake, IL
- Eligibility basics
- Ages 18–65